Efficacy and safety of dovitinib in pretreated advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase II study

被引：2
|
作者：
Ahn, Myung-Ju [1 ]
Lim, Sung Hee [1 ]
Sun, Jong -Mu [1 ]
Choi, Yoon-La [1 ]
Kim, Hye Ryun [2 ]
Ahn, Soo-min [1 ]
Lee, Se-Hoon [1 ]
Ahn, Jin Seok [1 ]
Park, Keunchil [1 ]
Kim, Joo Hang [2 ]
Cho, Byoung Chul [2 ]
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Yunsei Univ, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 02期
关键词：
D O I：
10.1016/j.jtho.2015.12.027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S16 / S16
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial
    Gao, Ming
    Zhang, Xia
    Yan, Huan
    Zhao, Yan
    Yuan, Fang
    Sun, Decong
    Yang, Xuejiao
    Ju, Yanfang
    Wang, Lijie
    Tao, Haitao
    Tian, Luyuan
    Zhao, Changhong
    Ma, Junxun
    Hu, Yi
    Liu, Zhefeng
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [42] FGFR1 amplification and EGFR mutation in Chinese squamous cell lung cancer.
    Wei, Zhigang
    Wang, Jie
    Bai, Hua
    An, Tongtong
    Wang, Zhijie
    Zhuo, Minglei
    Wu, Meina
    Yang, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] Anlotinib in elderly patients with advanced non-squamous non-small cell lung cancer (NSCLC) who had not received systemic chemotherapy: A single-arm, multi-center, phase II study
    Zhao, D.
    Hou, X.
    Li, Z.
    Yang, L.
    Hou, X.
    Li, H.
    Yan, L.
    Liu, H.
    Li, Z.
    Liu, X.
    Song, F.
    Li, G.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S1022 - S1022
  • [44] Phase II study of celecoxib and weekly paclitaxel in the treatment of pretreated advanced non-small cell lung cancer (NSCLC).
    Stani, SC
    Carillio, G
    Meo, S
    Morabito, A
    Bonginelli, P
    Comella, G
    Mansueto, G
    Avallone, A
    Gion, M
    Gasparini, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 700S - 700S
  • [45] Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study
    Lu, Shun
    Zhou, Jian-Ying
    Niu, Xiao-Min
    Zhou, Jian-Ya
    Jian, Hong
    Yin, Hong-Yan
    Guan, Sha
    Wang, Lin-Fang
    Li, Ke
    He, James
    Su, Wei-Guo
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (02) : 839 - +
  • [46] Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
    Chaft, Jamie E.
    Oezkan, Filiz
    Kris, Mark G.
    Bunn, Paul A.
    Wistuba, Ignacio I.
    Kwiatkowski, David J.
    Owen, Dwight H.
    Tang, Yan
    Johnson, Bruce E.
    Lee, Jay M.
    Lozanski, Gerard
    Pietrzak, Maciej
    Seweryn, Michal
    Byun, Woo Yul
    Schulze, Katja
    Nicholas, Alan
    Johnson, Ann
    Grindheim, Jessica
    Hilz, Stephanie
    Shames, David S.
    Rivard, Chris
    Toloza, Eric
    Haura, Eric B.
    McNamee, Ciaran J.
    Patterson, G. Alexander
    Waqar, Saiama N.
    Rusch, Valerie W.
    Carbone, David P.
    NATURE MEDICINE, 2022, 28 (10) : 2155 - +
  • [47] Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
    Jamie E. Chaft
    Filiz Oezkan
    Mark G. Kris
    Paul A. Bunn
    Ignacio I. Wistuba
    David J. Kwiatkowski
    Dwight H. Owen
    Yan Tang
    Bruce E. Johnson
    Jay M. Lee
    Gerard Lozanski
    Maciej Pietrzak
    Michal Seweryn
    Woo Yul Byun
    Katja Schulze
    Alan Nicholas
    Ann Johnson
    Jessica Grindheim
    Stephanie Hilz
    David S. Shames
    Chris Rivard
    Eric Toloza
    Eric B. Haura
    Ciaran J. McNamee
    G. Alexander Patterson
    Saiama N. Waqar
    Valerie W. Rusch
    David P. Carbone
    Nature Medicine, 2022, 28 : 2155 - 2161
  • [48] Single-arm, phase II study of pyrotinib in advanced non-small cell lung cancer (NSCLC) patients with HER2 exon 20 mutation.
    Gao, Guanghui
    Li, Xingya
    Wang, Qiming
    Zhang, Yiping
    Chen, Jianhua
    Shu, Yongqian
    Hu, Yanping
    Fan, Yun
    Fang, Jian
    Chen, Gongyan
    Zhao, Jun
    He, Jianxing
    Wu, Fengying
    Zou, Jianjun
    Zhu, Xiaoyu
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response
    Bogatyrova, Olga
    Mattsson, Johanna S. M.
    Ross, Edith M.
    Sanderson, Michael P.
    Backman, Max
    Botling, Johan
    Brunnstrom, Hans
    Kurppa, Pinja
    La Fleur, Linnea
    Strell, Carina
    Wilm, Claudia
    Zimmermann, Astrid
    Esdar, Christina
    Micke, Patrick
    EUROPEAN JOURNAL OF CANCER, 2021, 151 : 136 - 149
  • [50] Erlotinib treatment in pretreated patients with non-small cell lung cancer: A Phase II study
    Stathopoulos, G. P.
    Trafalis, D.
    Dimitroulis, J.
    Athanasiou, A.
    Koutantos, J.
    Anagnostopoulos, A.
    ONCOLOGY LETTERS, 2010, 1 (02) : 335 - 338
12345